# Supernus Pharmaceuticals

Type: Company (SUPN)

Source: GetYourBrief — https://getyourbrief.com/entity/supernus-pharmaceuticals
Canonical HTML page: https://getyourbrief.com/entity/supernus-pharmaceuticals

## Timeline

- **2026-10**: Expected Deal Close — The all-stock merger is anticipated to close, pending shareholder and regulatory approvals.
- **2026-08-03**: Merger and Earnings Announcement — Supernus unveils definitive agreement to merge with Indivior and releases Q2 2026 financial results.

## Recent coverage (6 stories, network-wide)

### Supernus–Indivior Merger Creates 11-Drug CNS Giant, $125M Synergy Target
2026-08-04 00:21:58 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 4

Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.
Full story: https://gethealthbrief.com/story/supernus-indivior-cns-merger-125m-synergy

### Sector Divergence: Q4 2025 Earnings Reveal Resilience in MedTech and Retail
2026-02-26 22:41:01 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 7

A wave of Q4 2025 earnings reports from mid-cap leaders across healthcare, automotive, and retail sectors highlights a bifurcated recovery. While MedTech and high-end retail show margin expansion, the EV and industrial sectors continue to navigate significant production and scaling headwinds.
Full story: https://getfinancebrief.com/story/novocure-lucid-q4-2025-earnings-analysis

### NovoCure and Supernus Signal Growth in Q4 2025 Earnings Amid Product Expansions
2026-02-26 22:39:51 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 7

NovoCure and Supernus Pharmaceuticals reported Q4 2025 results, highlighting a pivotal year for commercial expansion in oncology and CNS markets. Both companies are navigating the transition from R&D-heavy phases to sustained commercial growth following key regulatory milestones.
Full story: https://getbiobrief.com/story/novocure-supernus-q4-2025-earnings-analysis

### Axon Enterprise Eyes Software Growth as Q4 Earnings Approach
2026-02-23 22:52:45 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Axon Enterprise is set to report Q4 2025 results, with investors focused on the adoption of AI-driven tools like Draft One and the continued rollout of TASER 10. Meanwhile, specialty pharma players Corcept and Supernus prepare to disclose their own year-end performance amid shifting regulatory and competitive landscapes.
Full story: https://getfinancebrief.com/story/axon-enterprise-q4-2025-earnings-preview

### Pharma Earnings Preview: Supernus and Corcept Set for Q4 2025 Results
2026-02-23 22:52:13 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Supernus Pharmaceuticals and Corcept Therapeutics are preparing to report Q4 2025 results, with investors focusing on CNS product growth and cortisol-modulating pipeline progress. These reports will provide critical data on market penetration for key therapies like Qelbree and Korlym amidst a shifting regulatory landscape.
Full story: https://getbiobrief.com/story/supernus-corcept-q4-2025-earnings-preview

### Q4 Earnings Preview: Axon, Supernus, and Corcept Set for Key Results
2026-02-23 22:51:40 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Investors are bracing for Q4 2025 results from Axon Enterprise, Supernus Pharmaceuticals, and Corcept Therapeutics, with Axon looking to maintain its perfect revenue beat streak. While Axon dominates the public safety tech space, the pharmaceutical players face varying expectations regarding clinical pipelines and market penetration for core therapies.
Full story: https://gethealthbrief.com/story/q4-earnings-preview-axon-supernus-corcept

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.